イマイ　カズオ   IMAI Kazuo   今井　一男    所属   埼玉医科大学  医学部 臨床検査医学（中央検査部）    職種   専任講師
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression.
掲載誌名	正式名：Journal of pharmacological sciences
巻・号・頁	150(1),21-30頁
著者・共著者	Noriaki Arakawa,Shinichiro Matsuyama,Masaru Matsuoka,Isao Kitamura,Keiko Miyashita,Yutaro Kitagawa,Kazuo Imai,Kumiko Ogawa,Takuya Maeda,Yoshiro Saito,Chihiro Hasegawa
発行年月	2022/09
概要	The prognosis of patients with severe cases of COVID-19 is poor; thus, biomarkers for earlier prediction of COVID-19 progression are vital. We measured levels of five lung injury-related biomarkers, SP-D, KL-6, presepsin, kallistatin and stratifin, in serum samples collected serially during hospitalization from 31 patients with mild/moderate or severe/critical COVID-19 pneumonia, and their predictive performances were compared. Like the previously reported presepsin, a new biomarker candidate, stratifin, was significantly elevated with the onset of severe or critical symptoms in COVID-19 patients and decreased with symptom improvement. Notably, changes in stratifin and presepsin levels were distinctly earlier than those in SP-D, KL-6 and even SpO2/FiO2 values. Furthermore, serum levels of these biomarkers were significantly higher at the pre-severe stage (before the start of oxygen support) of patients whoeventually advanced to severe/critical stages than in the patients who remained at the mild/moderate stage. These results were confirmed in an independent cohort, including 71 mild/moderate and 14 severe/critical patients, for whom the performance of stratifin and presepsin in di
DOI	10.1016/j.jphs.2022.06.002
PMID	35926945